Skip to Content

Exceptional Response of Lorlatinib and Cabozantinib Combination in ROS1-Rearranged NSCLC

In this MEDtalk, Assistant Professor Tejas Patil presents a case with one of his patients having an exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance.

Tejas Patil

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top